Immunother Limited announced today that they will be expanding their current Shenzhen facility.
Online PR News – 15-July-2020 – SHENZHEN – The expansion is set to start in August and is expected to be completed by January 2021 and Immunother Limited will use this medical technology corridor to increase efficiencies and support growth
Immunother Limited’s current Shenzhen biotech facility will now be expanded to 130,000 square-foot and will include a state of the art biotech research facility with the capacity for more employees.
Immunother Limited’s Director, Mr. Lin Zhang commented on the Shenzhen expansion saying "We are excited to expand our biotech facility to provide more space and capacity for our growing company. Our facility will allow for more increased efficiency and cost savings that will help improve productivity, enabling us to scale our company as we continue to grow, and better serve our people around the globe."
About Us - Immunother Limited
Immunother Limited Company is a privately held Shenzen-based preclinical stage biotechnology company focused on discovering and developing novel therapies for inflammatory diseases.
Immunother Limited Company creates lasting value through pioneering research in the field of immunology which leads to new product concepts, product development, and finally to the licensing of those products and associated intellectual property.